Primary endpoint achieved with >99% nasal bacterial load reduction (p<0.0001)
Excellent safety profile. No treatment related adverse events
Brighton, United Kingdom – 29th March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces positive top-line results from its Phase 2b clinical study testing its XF-73 nasal gel as a new product for the prevention of the incidence of post-surgical infections such as methicillin-resistant Staphylococcus aureus (MRSA). The primary efficacy endpoint was met with an exceptionally high statistical significance and there were no treatment related safety events.